Showing results (351-360 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|January 7, 2023
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, et al.
NPJ Breast Cancer|November 23, 2022
Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancerFengling Li, Yongquan Yang, Yani Wei, et al.
NPJ Breast Cancer|June 1, 2021
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancerZhenbo Tu, Johannes Schmoellerl, Odette Mariani, et al.
NPJ Breast Cancer|June 2, 2021
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancerRui Luo, Weelic Chong, Qiang Wei, et al.
NPJ Breast Cancer|June 8, 2021
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancersLeticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, et al.
NPJ Breast Cancer|June 23, 2021
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroupsStephen Johnston, Joyce O'Shaughnessy, Miguel Martin, et al.
NPJ Breast Cancer|June 8, 2022
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significantLizelle Correia, Ramiro Magno, Joana M Xavier, et al.
NPJ Breast Cancer|June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysisLisa A Carey, Delphine Loirat, Kevin Punie, et al.
NPJ Breast Cancer|May 10, 2022
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancerAdrienne G Waks, Neelam V Desai, Tianyu Li, et al.
NPJ Breast Cancer|May 29, 2021
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activitySimon Timbrell, Hosam Aglan, Angela Cramer, et al.
Pageof 98